Stryker (SYK) Receives a Buy from Morgan Stanley
In a report released today, Patrick Wood from Morgan Stanley maintained a Buy rating on Stryker, with a price target of $445.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Wood is a 3-star analyst with an average return of 2.0% and a 56.88% success rate. Wood covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Dexcom, and Tandem Diabetes Care.
In addition to Morgan Stanley, Stryker also received a Buy from TipRanks – OpenAI’s OpenAI Medical – Devices in a report issued on January 31. However, on the same day, TipRanks – Anthropic reiterated a Hold rating on Stryker (NYSE: SYK).
Based on Stryker’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.17 billion and a net profit of $849 million. In comparison, last year the company earned a revenue of $6.44 billion and had a net profit of $546 million
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Most recently, in November 2025, William E. Berry, the VP & CAO of SYK sold 1,953.00 shares for a total of $713,801.97.
Read More on SYK:
